Modulation of the genotoxicity of bleomycin by amines through noncovalent DNA interactions and alteration of physiological conditions in yeast

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 623, Issue 1-2, 2007, Pages 41-52

  Hoffmann, George R ^a   Gessner, Gabrielle S ^a   Hughes, Jennifer F ^a   Ronan, Matthew V ^a   Sylvia, Katelyn E ^a   Willett, Christine J ^a  

^a Center for Interdisciplinary Studies   (United States)

Author keywords

Aminothiols; Antimutagen; Bleomycin; Genotoxicity; Intercalation; Mitotic recombination; Mutagen interactions; Pargyline; Polyamines; Recombinagen; Synergy; Yeast

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); AMINOACRIDINE; AMINOTHIOL; BLEOMYCIN; CYSTEAMINE DERIVATIVE; DEOXYRIBOSE; DIETHYLENETRIAMINE; ETHYLAMINE; ETHYLENEDIAMINE; PARGYLINE; POLYAMINE; POLYAMINE OXIDASE; PUTRESCINE; SPERMIDINE; SPERMINE;

ARTICLE; DRUG DNA INTERACTION; DRUG EFFECT; FUNGAL STRAIN; GENE CONVERSION; GENE LOCUS; GENOTOXICITY; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; YEAST;

AMINES; BLEOMYCIN; DNA, FUNGAL; DRUG INTERACTIONS; GENE CONVERSION; GENES, FUNGAL; MUTAGENS; SACCHAROMYCES CEREVISIAE;

SACCHAROMYCES CEREVISIAE;

EID: 34548430039     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2007.02.008     Document Type: Article

References (57)

1. Povirk L.F., and Austin M.J.F. Genotoxicity of bleomycin. Mutat. Res. 257 (1991) 127-143
2. Burger R.M. Cleavage of nucleic acids by bleomycin. Chem. Rev. 98 (1998) 1153-1169
3. Hecht S.M. Bleomycin: New perspectives on the mechanism of action. J. Nat. Prod. 63 (2000) 158-168
4. Chen J., and Stubbe J. Bleomycins: towards better therapeutics. Nat. Rev. Cancer 5 (2005) 102-112
5. Stubbe J., Kozarich J.W., Wu W., and Vanderwall D.E. Bleomycins: a structural model for specificity, binding, and double strand cleavage. Acc. Chem. Res. 29 (1996) 322-330
6. Hay J., Shahzeidi S., and Laurent G. Mechanisms of bleomycin-induced lung damage. Arch. Toxicol. 65 (1991) 81-94
7. Povirk L.F. DNA damage and mutagenesis by radiomimetic DNA-cleaving agents: bleomycin, neocarzinostatin and other enediynes. Mutat. Res. 355 (1996) 71-89
8. 0 human lymphocytes. Environ. Mol. Mutagen. 37 (2001) 117-127
9. 0 human lymphocytes. Mutat. Res. 307 (1994) 273-283
10. Ramel C., Alekperov U.K., Ames B.N., Kada T., and Wattenberg L.W. Inhibitors of mutagenesis and their relevance to carcinogenesis. Mutat. Res. 168 (1986) 47-65
11. Hartman P.E., and Shankel D.M. Antimutagens and anticarcinogens: a survey of putative interceptor molecules. Environ. Mol. Mutagen. 15 (1990) 145-182
12. Waters M.D., Brady A.L., Stack H.F., and Brockman H.E. Antimutagenicity profiles for some model compounds. Mutat. Res. 238 (1990) 57-85
13. DeMarini D.M. Environmental mutagens/complex mixtures. In: Li A.P., and Heflich R.H. (Eds). Genetic Toxicology (1991), CRC Press, Boca Raton, FL 285-302
14. Ferguson L.R. Antimutagens as cancer chemopreventive agents in the diet. Mutat. Res. 307 (1994) 395-410
15. Hoffmann G.R., Quaranta J.L., Shorter R.A., and Littlefield L.G. Modulation of bleomycin-induced mitotic recombination in yeast by the aminothiols cysteamine and WR-1065. Mol. Gen. Genet. 249 (1995) 366-374
16. Hoffmann G.R., Shorter R.A., Quaranta J.L., and McMaster P.D. Two mechanisms of antimutagenicity of the aminothiols cysteamine and WR-1065 in Saccharomyces cerevisiae. Toxicol. In Vitro 13 (1999) 1-9
17. Chatterjee A., Jacob-Raman M., and Mohapatra B. Potentiation of bleomycin-induced chromosome aberrations by the radioprotector reduced glutathione. Mutat. Res. 214 (1989) 207-213
18. 0 human lymphocytes. Toxicol. Lett. 78 (1995) 147-151
19. Zimmermann F.K. Procedures used in the induction of mitotic recombination and mutation in the yeast Saccharomyces cerevisiae. Mutat. Res. 31 (1975) 71-86
20. Zimmermann F.K. Tests for recombinagens in fungi. Mutat. Res. 284 (1992) 147-158
21. Zimmermann F.K., Kern R., and Rasenberger H. A yeast strain for the simultaneous detection of induced mitotic crossing over, mitotic gene conversion and reverse mutation. Mutat. Res. 28 (1975) 381-388
22. Zimmermann F.K., von Borstel R.C., von Halle E.S., Parry J.M., Siebert D., Zetterberg G., Barale R., and Loprieno N. Testing of chemicals for genetic activity with Saccharomyces cerevisiae: a report of the U.S. Environmental Protection Agency Gene-Tox Program. Mutat. Res. 133 (1984) 199-244
23. Feuerstein B.G., Pattabiraman N., and Marton L.J. Spermine-DNA interactions: a theoretical study. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 5948-5952
24. Strekowski L., Harden D.B., Wydra R.L., Stewart K.D., and Wilson W.D. Molecular basis for the potentiation of bleomycin-mediated degradation of DNA by polyamines. Experimental and molecular mechanical studies. J. Mol. Recognit. 2 (1989) 158-166
25. Bloomfield V.A. DNA condensation by multivalent cations. Biopolymers 44 (1994) 269-282
26. Sy D., Durand C., Hugot S., Savoye C., Swenberg C., Charlier M., and Spotheim-Maurizot M. Sequence dependence of DNA radioprotection by the thiols WR-1065 and WR-151326. Theor. Chem. Acct. 101 (1999) 114-120
27. Pastré D., Piétrement O., Landousy F., Hamon L., Sorel I., David M.-O., Delain E., Zozime A., and Le Cam E. A new approach to DNA bending by polyamines and its implication in DNA condensation. Eur. Biophys. J. 35 (2006) 214-223
28. López-Larraza D.M., Padrón J., Ronci N.E., Vidal L.A., and Rioja. Chromatin condensation and differential sensitivity of mammalian and insect cells to DNA strand breaks induced by bleomycin. Mutat. Res. 600 (2006) 93-101
29. Newton G.L., Aguilera J.A., Ward J.F., and Fahey R.C. Effect of polyamine-induced compaction and aggregation of DNA on the formation of radiation-induced strand breaks: quantitative models for cellular radiation damage. Radiat. Res. 148 (1997) 272-284
30. Chiu S.-m., and Oleinick N.L. Radioprotection against the formation of DNA double-strand breaks in cellular DNA but not native cellular chromatin by the polyamine spermine. Radiat. Res. 148 (1997) 188-192
31. Aouida M., Leduc A., Wang H., and Ramotar D. Characterization of a transport and detoxification pathway for the antitumour drug bleomycin in Saccharomyces cerevisiae. Biochem. J. 384 (2004) 47-58
32. Smoluk G.D., Fahey R.C., and Ward J.F. Interaction of glutathione and other low-molecular-weight thiols with DNA: evidence for counterion condensation and coion depletion near DNA. Radiat. Res. 114 (1988) 3-10
33. De Flora S., Rosenkranz H.S., and Klopman G. Structural basis of antimutagenicity of chemicals towards 4-nitroquinoline 1-oxide in Salmonella typhimurium. Mutagenesis 9 (1994) 39-45
34. Nagy B., and Grdina D.J. Protective effects of 2-[(aminopropyl)amino] ethanethiol against bleomycin and nitrogen mustard-induced mutagenicity in V79 cells. Int. J. Radiat. Oncol. Biol. Phys. 12 (1986) 1475-1478
35. Buschini A., Alessandrini C., Martino A., Pasini L., Rizzoli V., Carlo-Stella C., Poli P., and Rossi C. Bleomycin genotoxicity and amifostine (WR-2721) cell protection in normal leukocytes vs. K562 tumoral cells. Biochem. Pharmacol. 63 (2002) 967-975
36. Capizzi R.L. Clinical status and optimal use of amifostine. Oncology 13 (1999) 47-59
37. Hospers G.A.P., Eisenhauer E.A., and de Vries E.G.E. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects. Br. J. Cancer 80 (1999) 629-638
38. Nici L., and Calabresi P. Amifostine modulation of bleomycin-induced lung injury in rodents. Semin. Oncol. 26 suppl. 7 (1999) 28-33
39. Ortiz L.A., Lasky J.A., Safah H., Reyes M., Miller A., Lungarella G., and Friedman M. Exacerbation of bleomycin-induced lung injury in mice by amifostine. Am. J. Physiol. 277 (1999) L1239-L1244
40. Parkinson A. Biotransformation of xenobiotics. In: Klaassen C.D. (Ed). Casarett & Doull's Toxicology: The Basic Science of Poisons. sixth ed. (2001), McGraw-Hill, New York 133-224
41. Moskvitina T.A., and Medvedev A.E. Differential sensitivity of mitochondrial and cytosolic monoamine oxidases to in vivo but not in vitro inhibition by specific irreversible inhibitors. Med. Sci. Monit. 7 (2001) 17-19
42. Tabor C.W., and Tabor H. Polyamines. Ann. Rev. Biochem. 53 (1984) 749-790
43. Snyder R.D., Ewing D.E., and Hendry L.B. Evaluation of DNA intercalation potential of pharmaceuticals and other chemicals by cell-based and three-dimensional computational approaches. Environ. Mol. Mutagen. 44 (2004) 163-173
44. Snyder R.D., and Hendry L.B. Toward a greater appreciation of noncovalent chemical/DNA interactions: application of biological and computational approaches. Environ. Mol. Mutagen. 45 (2005) 100-105
45. Xu H.E., and Johnston S.A. Yeast bleomycin hydrolase is a DNA-binding cysteine protease. J. Biol. Chem. 269 (1994) 21177-21183
46. Joshua-Tor L., Xu E.H., Johnston S.A., and Rees D.C. Crystal structure of a conserved protease that binds DNA: the bleomycin hydrolase, Gal6. Science 269 (1995) 945-950
47. Neidle S., and Abraham Z. Structural and sequence-dependent aspects of drug intercalation into nucleic acids. CRC Crit. Rev. Biochem. 17 (1984) 73-121
48. Ferguson L.R., and Denny W.A. The genetic toxicology of acridines. Mutat. Res. 258 (1991) 123-160
49. Hoffmann G.R., Calciano M.A., Lawless B.M., and Mahoney K.M. Frameshift mutations induced by three classes of acridines in the lacZ reversion assay in Escherichia coli: potency of responses and relationship to slipped mispairing models. Environ. Mol. Mutagen. 42 (2003) 111-121
50. Ferguson L.R., and Denny W.A. Frameshift mutagenesis by acridines and other reversibly-binding DNA ligands. Mutagenesis 5 (1990) 529-540
51. O'Connor C.J., McLennan D.J., Denny W.A., and Sutton B.M. Substituent effects on the hydrolysis of analogues of nitracrine (9-[3-(N,N-dimethylamino)propylamino]-1-nitroacridine). J. Chem. Soc. Perkin. Trans. 2 (1990) 1637-1641
52. Siim B.G., Hicks K.O., Pullen S.M., van Zijl P.L., Denny W.A., and Wilson W.R. Comparison of aromatic and tertiary amine N-oxides of acridine DNA intercalators as bioreductive drugs: cytotoxicity, DNA binding, cellular uptake, and metabolism. Biochem. Pharmacol. 60 (2000) 969-978
53. Hoffmann G.R., Yin C.C., Terry C.E., Ferguson L.R., and Denny W.A. Frameshift mutations induced by four isomeric nitroacridines and their des-nitro counterpart in the lacZ reversion assay in Escherichia coli. Environ. Mol. Mutagen. 47 (2006) 82-94
54. Snyder R.D., and Diehl M.S. The bleomycin amplification assay in V79 cells predicts frameshift mutagenicity of intercalative agents. Mutagenesis 15 (2000) 203-205
55. Surh Y.-J., and Ferguson L.R. Dietary and medicinal antimutagens and anticarcinogens: molecular mechanisms and chemopreventive potential-highlights of a symposium. Mutat. Res. 523-524 (2003) 1-8
56. De Flora S., and Ferguson L.R. Overview of mechanisms of cancer chemopreventive agents. Mutat. Res. 591 (2005) 8-15
57. Zeiger E. Illusions of safety: antimutagens can be mutagens, and anticarcinogens can be carcinogens. Mutat. Res. 543 (2003) 191-194